Keros Therapeutics, Inc.

NasdaqGM:KROS Stock Report

Market Cap: US$219.7m

Keros Therapeutics Valuation

Is KROS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KROS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate KROS's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate KROS's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KROS?

Key metric: As KROS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for KROS. This is calculated by dividing KROS's market cap by their current revenue.
What is KROS's PS Ratio?
PS Ratio14.6x
SalesUS$15.01m
Market CapUS$219.69m

Price to Sales Ratio vs Peers

How does KROS's PS Ratio compare to its peers?

The above table shows the PS ratio for KROS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.9x
CUE Cue Biopharma
5.5x-19.15%US$208.8m
IVVD Invivyd
4x54.21%US$231.5m
XFOR X4 Pharmaceuticals
21.9x71.16%US$347.0m
ABEO Abeona Therapeutics
12.1x42.22%US$309.7m
KROS Keros Therapeutics
14.6x48.00%US$219.7m

Price-To-Sales vs Peers: KROS is expensive based on its Price-To-Sales Ratio (14.6x) compared to the peer average (10.9x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does KROS's PS Ratio compare vs other companies in the US Biotechs Industry?

122 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
3.2x2.60%US$32.08b
BMRN BioMarin Pharmaceutical
3.7x10.33%US$12.71b
LEGN Legend Biotech
2.8x15.48%US$3.61b
SRPT Sarepta Therapeutics
1.1x-11.00%US$2.16b
KROS 14.6xIndustry Avg. 12.3xNo. of Companies122PS01632486480+
122 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: KROS is expensive based on its Price-To-Sales Ratio (14.6x) compared to the US Biotechs industry average (12.3x).

Price to Sales Ratio vs Fair Ratio

What is KROS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KROS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14.6x
Fair PS Ratio0.02x

Price-To-Sales vs Fair Ratio: KROS is expensive based on its Price-To-Sales Ratio (14.6x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst KROS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$11.08
US$19.83
+79.00%
16.32%US$25.00US$16.00n/a6
Sep ’27US$11.07
US$19.83
+79.16%
16.32%US$25.00US$16.00n/a6
Aug ’27US$10.07
US$21.83
+116.82%
20.55%US$30.00US$16.00n/a6
Jul ’27US$10.88
US$21.83
+100.67%
20.55%US$30.00US$16.00n/a6
Jun ’27US$10.90
US$21.83
+100.31%
20.55%US$30.00US$16.00n/a6
May ’27US$11.49
US$22.57
+96.44%
20.07%US$30.00US$16.00n/a7
Apr ’27US$11.69
US$22.57
+93.08%
20.07%US$30.00US$16.00n/a7
Mar ’27US$14.19
US$23.00
+62.09%
19.16%US$30.00US$16.00n/a7
Feb ’27US$17.91
US$23.50
+31.21%
22.82%US$35.00US$16.00n/a8
Jan ’27US$20.36
US$23.38
+14.81%
23.33%US$35.00US$16.00n/a8
Dec ’26US$17.18
US$23.38
+36.06%
23.33%US$35.00US$16.00n/a8
Nov ’26US$15.22
US$23.00
+51.12%
24.60%US$35.00US$15.00n/a8
Oct ’26US$15.28
US$23.00
+50.52%
24.60%US$35.00US$15.00n/a8
Sep ’26US$15.21
US$23.00
+51.22%
24.60%US$35.00US$15.00US$11.078
Aug ’26US$14.32
US$24.00
+67.60%
21.96%US$35.00US$15.00US$10.079
Jul ’26US$13.34
US$29.20
+118.89%
56.10%US$76.00US$15.00US$10.8810
Jun ’26US$14.15
US$30.60
+116.25%
52.15%US$76.00US$15.00US$10.9010
May ’26US$14.57
US$33.70
+131.30%
47.83%US$76.00US$15.00US$11.4910
Apr ’26US$9.55
US$35.50
+271.73%
45.22%US$76.00US$15.00US$11.6910
Mar ’26US$11.08
US$33.64
+203.58%
48.76%US$76.00US$15.00US$14.1911
Feb ’26US$11.40
US$34.36
+201.44%
48.59%US$76.00US$15.00US$17.9111
Jan ’26US$15.83
US$43.55
+175.08%
33.33%US$76.00US$23.00US$20.3611
Dec ’25US$57.74
US$90.69
+57.07%
12.00%US$107.00US$76.00US$17.1813
Nov ’25US$59.94
US$89.33
+49.04%
11.56%US$105.00US$76.00US$15.2212
Oct ’25US$59.79
US$90.90
+52.03%
11.49%US$105.00US$76.00US$15.2810
Sep ’25US$45.35
US$90.89
+100.42%
11.25%US$105.00US$77.00US$15.219
US$19.83
Fair Value
44.1% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 17:16
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Keros Therapeutics, Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Corinne JohnsonGoldman Sachs
Andrew FeinH.C. Wainwright & Co.